Retatrutide is the triple-agonist GLP-1/GIP/glucagon peptide that produced the largest weight-loss numbers seen in any obesity drug trial so far outperforming Ozempic and Mounjaro. It activates three receptors at once (GLP-1, GIP, and glucagon), which is what separates it from semaglutide and...